Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial

N Potere, M Di Nisio, E Porreca, TF Wang… - Thrombosis research, 2023 - Elsevier
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …
被引用次数：5 相关文章

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.

N Potere, M Di Nisio, E Porreca, TF Wang… - Thrombosis …, 2023 - europepmc.org
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

N Potere, M di Nisio, E Porreca… - Thrombosis …, 2023 - researchinformation.amsterdamumc …
Background: The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

N Potere, M Di Nisio, E Porreca, TF Wang, V Tagalakis… - 2023 - pubmed.ncbi.nlm.nih.gov
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

N Potere, M Di Nisio, E Porreca, TF Wang… - THROMBOSIS …, 2023 - ricerca.unich.it
Background: The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

N Potere, M Di Nisio, E Porreca… - Thrombosis …, 2023 - thrombosisresearch.com
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

N Potere, M Di Nisio, E Porreca, TF Wang… - THROMBOSIS …, 2023 - ricerca.unich.it
Background: The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …